20/20 Biolabs Inc (NASDAQ: AIDX) is a diagnostics company that develops and runs laboratory-based blood tests for cancer screening and inflammatory biomarker measurement. Revenue is generated through the sale of lab tests, with a secondary CLIAx business that hosts overseas diagnostics start-ups in its shared CLIA laboratory. The company operates two product families under the OneTest brand: OneTest for Cancer, a multi-cancer early detection test, and OneTest for Longevity, an inflammatory biomarker panel launched in February 2026 and also marketed as OneTest for Workplace Wellness to self-insured employers. Both tests are processed in the company's CAP-accredited, CLIA-licensed laboratory in Gaithersburg, MD. Financing as of the 10-K filed March 31, 2026 includes secured convertible promissory notes issued to Streeterville Capital, LLC, indicating a debt-dependent capital structure at an early commercial stage.

Revenue model

Transactional test sales to consumers, employers, and potentially healthcare partners. The Longevity test is marketed to self-insured employers under the Workplace Wellness brand. The CLIAx shared laboratory hosts overseas diagnostics start-ups for fees. A license agreement with ROKIT Healthcare (signed March 18, 2026) introduces a running royalty structure on net sales of a combined chronic kidney disease prediction product.

Products and services

OneTest for Cancer: a multi-cancer early detection test using capillary or venous blood, run in the company's Gaithersburg, MD laboratory. OneTest for Longevity: an inflammatory biomarker panel incorporating the Dietary Inflammatory Index (DII), licensed exclusively in North America from Connecting Health Innovations (CHI) on February 14, 2025. CLIAx: a shared CLIA laboratory service for overseas diagnostics start-ups. An AI avatar of nutritional epidemiologist James R. Hébert, Ph.D. is in development for use with the Longevity test.

Customers and end markets

Direct-to-consumer online purchasers, self-insured employers (Workplace Wellness channel), and potentially pharmacy and workplace settings enabled by fingerstick capillary blood collection. Strategic drug and medical device partners treating chronic diseases are a targeted future channel.

Value-chain role

Vertically integrated diagnostics operator: test development, CAP-accredited and CLIA-licensed laboratory processing in Gaithersburg, MD, result reporting, and licensed IP integration (DII from CHI; chronic kidney disease algorithm from ROKIT Healthcare).

Geographic exposure

Primary operations in the United States. Exclusive North American license for the DII from CHI (as of February 14, 2025). ROKIT Healthcare agreement (March 18, 2026) contemplates potential future commercialization in Korea and other East Asian markets.

Source: SEC 10-K, filed 2026-03-31

Industry: Services-Testing Laboratories